Auriculotherapy Treatment in Fibromyalgia

NCT02764788 | Completed

• 2 other identifiers: 2015/272015-A01842-47
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Fibromyalgia (FM) is the most common cause of diffuse pain in the bones and joints, and one of the most frequent causes of referral to the pain management unit. It affects mainly women; they are referred by a rheumatologist, an internal medicine physician or by their family physician. FM produces various degrees of disability and pain, and has an important impact on quality of life. Sleep disorders, fatigue and cognitive dysfunctions are almost always part of the clinical presentation. The wide range of symptoms and signs, the unknown etiology, the lack of efficacy of pharmacological treatments make management of FM a very difficult task. In France the consensus includes limitation of pharmacological treatment, encouraging physical rehabilitation and referring the patients to a specialized pain clinic where multidisciplinary management will be undertaken. In our hospital the investigators favor non pharmacological therapies and propose to the FM patients to learn relaxation and self-hypnosis, physical rehabilitation and use of trans cutaneous electrical neurostimulation. Auriculotherapy (AT) is a complementary therapy, based on the idea that the ear is a microsystem which reflects the entire body, represented on the auricle, the outer portion of the ear. Mapping of the auricle has been described, according to the fact that pathology of different organs can induce specific changes in the auricle, for example color change or sensitivity. Treating specific areas, which somehow would be "connected" to the affected organ could also improve the functioning of the body or relieve pain. AT uses placement of needles at points tailored to the patient's pathology. Whatever the mechanisms involved, the effectiveness of ATis currently supported by randomized controlled trials. It is validated by WHO since 1987, mapped in an international nomenclature initially proposed by Nogier. The investigators regularly use AT in FM patients in our pain management unit to alleviate symptoms as pain, sleep disorders, anxiety. The investigators established a clinical trial in this population to assess impact of FM (assessed with Fibromyalgia Impact Questionnaire) following 3 months of AT management (Primary Outcome). Sleep disorder, fatigue, anxiety and depression, cognitive and physical dysfunction are also evaluated as secondary outcomes. The remnant effect of AT is also evaluated, 3 month after the end of the treatment by the same tests.

Conditions

Fibromyalgia

Keywords

Auriculotherapy

Outcome Measures

Primary Outcomes (1)

• Effect of otherapy on the health of patients with fibromyalgia syndrome

  3 months

Study Arms (3)

Specific auriculotherapy

EXPERIMENTAL

Auriculotherapy on specific points with needles

Other: Specific auriculotherapy

Non-specific auriculotherapy

SHAM COMPARATOR

Auriculotherapy on non-specific auriculotherapy points with needles

Other: non-specific auriculotherapy

Seed auriculotherapy

PLACEBO COMPARATOR

Auriculotherapy on non-specific auriculotherapy points with seeds

Other: seed auriculotherapy

Interventions

Specific auriculotherapy OTHER

Specific auriculotherapy with needles

Specific auriculotherapy

non-specific auriculotherapy OTHER

non-specific auriculotherapy with needles

Non-specific auriculotherapy

seed auriculotherapy OTHER

non-specific auriculotherapy with seeds

Seed auriculotherapy

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• fibromyalgia (criteria from ACR)

You may not qualify if:

• history or existing of inflammatory rheumatims, lupus, systemic diseases that may explain the pain syndrom
• history or existing of severe psychiatric desorder
• history or existing of hemophilia
• with anticoagulant treatment
• local counterindication to auriculotherapy
• valvular prosthesis
• auriculotherapy during the last 12 months
• new psychotherpeutic treatment which interfer with auriculotherapy
• pregnancy
• breath feeding
• RMI for the next 5 months

Sponsors & Collaborators

• Hopital Foch: lead

Study Sites (1)

Hopital Foch

Suresnes, 92150, France

Location

MeSH Terms

Conditions

Fibromyalgia

Condition Hierarchy (Ancestors)

Muscular Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Neuromuscular Diseases; Nervous System Diseases

Study Officials

• Mireille Michel-Cherqui, MD

  Hopital Foch

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 4, 2016
• First Posted: May 6, 2016
• Study Start: April 27, 2016
• Primary Completion: March 9, 2022
• Study Completion: March 9, 2022
• Last Updated: August 31, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)